CHS could slow pace of divestitures as it makes progress paying debt
Community Health Systems (CHS) plans to decelerate its hospital divestitures after making significant progress in debt reduction and improving cash flow. Since 2019, CHS has divested 35% of its hospital portfolio, paying down $1.1 billion in debt last year. Although early-phase discussions for some divestitures are ongoing, the company will now be more opportunistic, focusing on growth in core markets and expecting adjusted EBITDA between $1.3 billion and $1.5 billion for the current year.
Select Medical anticipates up to $5.8B revenue in 2026 while advancing inpatient rehab expansion
Select Medical projects revenues between $5.6 billion and $5.8 billion for 2026, driven by continued expansion in inpatient rehabilitation facilities and long-term care hospitals. The company is actively pursuing new joint venture opportunities and hospital expansions to meet strategic growth objectives. Despite a mixed performance in Q4 2025, with revenues up but earnings per share down, the company's long-term outlook remains positive with planned capacity additions.
June 2027 Options Now Available For HCA Healthcare
New options contracts for HCA Healthcare (HCA) with a June 2027 expiration date are now available, offering opportunities for investors. The article details a put option at a $500 strike price, which could allow investors to acquire shares at a discount or earn a 9.30% return if it expires worthless. Additionally, a covered call strategy with a $580 strike price is presented, potentially yielding a 20.11% total return if the stock is called away.
HCA Healthcare (NYSE:HCA) Given New $535.00 Price Target at JPMorgan Chase & Co.
JPMorgan Chase & Co. has raised its price target for HCA Healthcare (NYSE:HCA) from $420.00 to $535.00, suggesting a potential upside of 1.52% from its current price. HCA holds a consensus "Moderate Buy" rating with an average analyst target of $530.77. The company recently exceeded quarterly EPS estimates but slightly missed revenue projections, while setting an FY2026 EPS guidance above analyst forecasts.
Pediatrix Medical Q4 Earnings Miss Estimates Despite Declining Costs
Pediatrix Medical Group (MD) reported fourth-quarter 2025 adjusted earnings per share of 50 cents, falling short of the Zacks Consensus Estimate by 4.9%, despite a 2% year-over-year decline in the bottom line. Net revenues increased 0.5% year over year to $493.8 million, exceeding estimates. The company's results were negatively impacted by higher variable practice incentive compensation and lower-than-expected same-unit revenues, though these were partially offset by improved collection activity and lower operating expenses.
Vanguard Group Inc. Has $1.83 Billion Stock Position in Tenet Healthcare Corporation $THC
Vanguard Group Inc. recently trimmed its stake in Tenet Healthcare Corporation by 4.8% but still holds 9,009,590 shares, valued at approximately $1.83 billion, representing about 10.25% of the company. Tenet Healthcare exceeded Q3 earnings expectations and provided strong FY2026 guidance, leading analysts to raise price targets, with the stock currently holding a "Moderate Buy" consensus rating. Corporate insiders hold a small percentage, while institutional investors own the majority, and one director recently sold shares.
Persistent Asset Partners Ltd Takes $1 Million Position in HCA Healthcare, Inc. $HCA
Persistent Asset Partners Ltd acquired a new stake of 2,353 shares, valued at approximately $1.003 million, in HCA Healthcare, Inc. during the third quarter. Other institutional investors also adjusted their holdings in the company, while some insiders sold shares. Analysts currently rate HCA Healthcare as a "Moderate Buy" with a consensus price target of $523.27, and the company recently increased its quarterly dividend.
NEOS Investment Management LLC Has $3.71 Million Stock Position in ResMed Inc. $RMD
NEOS Investment Management LLC significantly increased its stake in ResMed Inc. ($RMD) by 49.1% in Q3, now holding 13,539 shares valued at approximately $3.71 million. This increase is part of a broader trend of institutional investment, with firms like Norges Bank and Vanguard Group Inc. also holding substantial positions, bringing institutional ownership to 54.98%. ResMed recently surpassed quarterly earnings estimates with an EPS of $2.81 and revenue of $1.42 billion, maintaining a "Moderate Buy" consensus rating from analysts with a target price of $299.27.
ResMed Inc. $RMD Shares Sold by BNP PARIBAS ASSET MANAGEMENT Holding S.A.
BNP PARIBAS ASSET MANAGEMENT Holding S.A. reduced its stake in ResMed Inc. ($RMD) by 17.5% in the third quarter, selling 41,123 shares. Despite this, other hedge funds increased their positions, and institutional investors now own 54.98% of the stock. Analysts maintain a "Moderate Buy" rating for ResMed, with a consensus price target of $299.27.
Community Health Systems (NYSE:CYH) Releases Quarterly Earnings Results, Beats Estimates By $1.00 EPS
Community Health Systems (NYSE:CYH) announced strong quarterly earnings, reporting $0.80 EPS, significantly beating analyst estimates of ($0.20) by $1.00. Despite a 4.9% decline in year-over-year revenue to $3.11 billion, the company updated its FY 2026 EPS guidance to a range of -0.60 to 0.00. Following the announcement, CYH shares saw a 3.1% increase, trading at $3.45.
DaVita Stock Is Up 35% Since February. Here’s Where Shares Could Go in 2026
DaVita (DVA) stock surged 35% in February 2026, driven by a strong Q4 2025 earnings beat, robust 2026 guidance forecasting a 33% EPS jump, and a strategic investment in Elara Caring to expand home kidney care. Analysts have raised price targets, recognizing DaVita's transition into a multi-vertical kidney care platform with significant upside potential, despite some near-term risks and Wall Street's cautious stance. TIKR's valuation model projects a mid-case target price of $217.26 by December 2030, suggesting a 47% total return.
HCA Healthcare EVP McAlevey sells $903k in stock
Michael R. McAlevey, EVP at HCA Healthcare, sold 1,694 shares of common stock for over $903,000 on February 18, 2026. He also exercised stock appreciation rights for 5,000 shares and disposed of 3,306 shares to cover tax obligations. Despite executive sales, InvestingPro notes management is aggressively buying back shares, contributing to high shareholder yield, and the company recently surpassed Q4 2025 EPS forecasts.
HCA Healthcare EVP McAlevey sells $903k in stock
Michael R. McAlevey, EVP at HCA Healthcare, sold 1,694 shares worth $903,536 and exercised stock appreciation rights for 5,000 shares worth $1,183,050. These transactions resulted in him owning 8,853 direct shares and 2,137 indirect shares. The company recently reported strong Q4 2025 earnings and received a raised price target from Bernstein SocGen Group due to efficient margins and robust share buybacks.
HCA Florida Healthcare opens ER in Shoppes at Mission Trace
HCA Florida Healthcare has opened a new freestanding emergency room in St. Augustine, located at 1780 Woodlawn Road within the Shoppes at Mission Trace. This 860-square-foot facility, costing approximately $14.8 million to build, is the health care group’s second ER in St. Johns County. It operates 24/7, offering 10 private rooms, a trauma bay, and various diagnostic services to enhance access to emergency care in the community.
Community Health Systems (NYSE:CYH) Releases FY 2026 Earnings Guidance
Community Health Systems (NYSE:CYH) has released its FY 2026 earnings guidance, projecting EPS between -0.600 and 0.000 and revenue of $11.6 billion to $12.0 billion, both falling below analysts' consensus estimates. Following this announcement, CYH shares saw a 2.5% decrease to $3.36, and analysts maintain a "Hold" rating with a consensus price target of $3.60. Institutional investors hold approximately 85% of the stock.
Nurse sues HCA Florida Palms West Hospital, security company 1 year after brutal patient attack
A nurse, Leelamma Lal, has filed a lawsuit against HCA Florida Palms West Hospital and Allied Universal Security one year after a brutal attack by a patient left her with life-altering injuries. The lawsuit alleges negligence in providing adequate security, citing a history of violence at the hospital and a flawed security contract. Lal and her family seek justice and accountability, emphasizing the need for healthcare worker safety and calling for changes beyond financial compensation.
Vanguard Group Inc. Acquires 293,515 Shares of ResMed Inc. $RMD
Vanguard Group Inc. increased its stake in ResMed Inc. by 1.6% in the third quarter, purchasing an additional 293,515 shares to own a total of 19,040,440 shares, valued at approximately $5.21 billion. ResMed reported strong quarterly earnings, beating analyst estimates with an EPS of $2.81 and revenue of $1.42 billion, an 11% increase year-over-year. The company maintains a "Moderate Buy" consensus rating from analysts with an average price target of $299.27, although insiders have recently been net sellers of the stock.
Long Term Care Market Outlook 2026-2033: Size, Demand Surge,
The Long Term Care market is projected to grow from USD 1,274.02 billion in 2025 to USD 1,757.13 billion by 2032, driven by increasing demand, technological advancements, and changing consumer behaviors. This report offers a comprehensive analysis of market dynamics, competitive landscape, key segments, and strategic opportunities for businesses looking to gain a competitive edge. It covers detailed insights on regional markets, consumer behavior, pricing structures, and profiles top companies like Brookdale Senior Living Inc. and Sunrise Senior Living, LLC.
HCA’s Buybacks And Facility Expansion Amid Policy Hit Might Change The Case For Investing In HCA (HCA)
HCA Healthcare (HCA) reported strong 2025 results with increased revenue and net income, alongside significant share repurchases and strategic facility expansions. However, the company faces a substantial policy headwind from the expected US$900 million earnings impact due to expiring enhanced Affordable Care Act subsidies in 2026. This article explores how HCA's capital allocation decisions, including expanded buybacks and facility investments, could influence its investment profile for long-term investors despite the looming policy risk.
Deep Dive: HCA Healthcare Navigates Policy Shifts and Market Volatility
HCA Healthcare, a dominant player in the American for-profit hospital sector, experienced a 4% stock retreat, sparking debate among investors. This dip occurred amidst post-pandemic volume surges, a cooling labor crisis, and impending federal healthcare policy changes. Despite record revenues and aggressive capital returns, the market is weighing HCA's operational excellence against these shifting regulatory tides, prompting a deep dive into whether this decline signals structural headwinds or is merely a transient correction.
W.G. Shaheen & Associates DBA Whitney & Co Sells 4,003 Shares of ResMed Inc. $RMD
W.G. Shaheen & Associates DBA Whitney & Co reduced its stake in ResMed Inc. by 7.5%, selling 4,003 shares and now holding 49,528 shares valued at $13.56 million. ResMed reported strong Q3 earnings, beating analyst estimates with EPS of $2.81 and revenue of $1.42 billion, an 11% increase year-over-year. The medical equipment provider also announced a quarterly dividend of $0.60 per share, and Wall Street analysts currently give the stock a "Moderate Buy" rating with an average price target of $299.27.
Vanguard Group Inc. Reduces Stock Holdings in HCA Healthcare, Inc. $HCA
Vanguard Group Inc. decreased its stake in HCA Healthcare, Inc. by 3.8% in Q3, selling over half a million shares, though it still held 6.53% of the company. Despite Vanguard's reduction, analysts maintain a "Moderate Buy" consensus with a $523.27 price target. HCA Healthcare reported strong Q4 earnings, surpassing expectations, and increased its quarterly dividend.
250,130 Shares in HCA Healthcare, Inc. $HCA Bought by Mondrian Investment Partners LTD
Mondrian Investment Partners LTD has acquired 250,130 shares of HCA Healthcare, Inc. (NYSE:HCA) valued at approximately $106.6 million, making it their 27th largest holding. HCA Healthcare recently surpassed quarterly earnings estimates with an EPS of $8.01, though revenue was slightly below forecasts, and the company raised its quarterly dividend to $0.78, reflecting a positive outlook despite some insider share sales. Analysts maintain a "Moderate Buy" consensus for HCA, with an average price target of $523.27.
HCA Healthcare, Inc. $HCA Stock Holdings Lowered by Skandinaviska Enskilda Banken AB publ
Skandinaviska Enskilda Banken AB publ reduced its stake in HCA Healthcare Inc. (NYSE:HCA) by 3.3% in the third quarter, selling 4,616 shares. Despite this, other institutional investors, including Cerity Partners LLC and Swiss National Bank, increased their holdings in the healthcare company. HCA Healthcare also announced an increased quarterly dividend of $0.78 per share and reported strong quarterly earnings, beating analyst estimates.
ResMed Inc. $RMD Shares Sold by ABN Amro Investment Solutions
ABN Amro Investment Solutions significantly reduced its stake in ResMed Inc. by 81.2% in the third quarter, selling 5,427 shares and retaining 1,257 shares valued at $344,000. Despite this, ResMed exceeded Q4 earnings expectations with EPS of $2.81 and revenue of $1.42 billion, also announcing a $0.60 quarterly dividend. While institutional investors generally hold a strong position, recent insider selling activity, including CEO Michael J. Farrell's sale of 4,991 shares, indicates some divestment by executives.
Charles River Laboratories (CRL) Q4 Earnings: What To Expect
Charles River Laboratories (CRL) is set to report its Q4 earnings on Wednesday. Analysts anticipate a 2.2% year-on-year revenue decline to $980.9 million and adjusted earnings of $2.35 per share. Despite solid past performance in beating revenue estimates, the stock has underperformed its peers recently, and ongoing economic uncertainties have impacted the broader drug development inputs & services segment.
HCA Healthcare, Inc.'s (NYSE:HCA) large institutional owners must be happy as stock continues to impress, up 8.6% over the past week
HCA Healthcare, Inc. (NYSE:HCA) has seen its stock price increase by 8.6% over the past week, bringing its one-year return to shareholders to 72%. Institutional investors, holding a 55% stake, are the largest ownership group and are likely pleased with this performance. While insiders have a meaningful stake worth US$1.6 billion, they have been selling shares recently, and the general public holds a 32% stake in the company.
HCA Healthcare, Inc. $HCA Shares Sold by Eagle Rock Investment Company LLC
Eagle Rock Investment Company LLC significantly reduced its stake in HCA Healthcare by 36.6% in the third quarter, selling 12,481 shares and now holding 21,632 shares valued at approximately $9.22 million. Other institutional investors showed mixed activity, with some increasing and others initiating positions. HCA Healthcare recently reported strong quarterly earnings, beating EPS estimates, and increased its quarterly dividend, despite some insider selling activity.
Caprock Group LLC Takes Position in Universal Health Services, Inc. $UHS
Caprock Group LLC has established a new position in Universal Health Services (NYSE:UHS) during the third quarter, purchasing 4,390 shares valued at approximately $897,000. Other institutional investors also increased their holdings, contributing to a total institutional ownership of 86.05%. Universal Health Services, trading at $234.86, has a market cap of $14.67 billion and a P/E ratio of 11.16, with analysts currently holding a "Hold" consensus rating and an average price target of $234.13.
Aberdeen Group plc Has $75.94 Million Stake in ResMed Inc. $RMD
Aberdeen Group plc reduced its stake in ResMed Inc. (NYSE:RMD) by 6.6% in the third quarter, now holding 276,973 shares valued at $75.94 million. Other institutional investors also adjusted their positions in ResMed, with some increasing and others initiating stakes. The article details ResMed's stock performance, recent earnings, dividend announcement, analyst ratings, and insider trading activity.
Aberdeen Group plc Has $58.64 Million Stock Position in HCA Healthcare, Inc. $HCA
Aberdeen Group plc reduced its stake in HCA Healthcare, Inc. by 13.4% in the third quarter, now owning 139,303 shares valued at approximately $58.64 million. Despite this reduction, HCA Healthcare has shown strong year-over-year performance, positive analyst sentiment, and increased its quarterly dividend. The article also notes recent insider stock sales and provides an overview of analyst ratings and the company's financial performance.
Shell Asset Management Co. Has $2 Million Stock Position in HCA Healthcare, Inc. $HCA
Shell Asset Management Co. significantly reduced its stake in HCA Healthcare by 67.4% in Q3, holding 4,691 shares valued at approximately $1.999 million. Despite this, HCA Healthcare reported strong Q3 earnings, surpassing analyst estimates, and increased its quarterly dividend. The company also saw positive sentiment from analysts and institutional investors, although insider selling activity has been notable.
ING Groep NV Makes New Investment in HCA Healthcare, Inc. $HCA
ING Groep NV recently acquired 2,405 shares of HCA Healthcare, Inc. valued at approximately $1.025 million. Other institutional investors also increased their stakes in HCA Healthcare, with the company's stock currently having a "Moderate Buy" rating and an average target price of $523.27 from analysts. The article also details recent insider selling, strong stock performance, a raised quarterly dividend, and key news impacting HCA Healthcare.
HCA Healthcare, Inc. $HCA Shares Sold by Cherokee Insurance Co
Cherokee Insurance Co reduced its stake in HCA Healthcare by 19.8% in Q3, selling 2,000 shares. Despite this, HCA Healthcare reported strong Q4 earnings, beat analyst expectations, and increased its quarterly dividend. However, significant insider selling from two senior VPs also occurred, totaling approximately $6.15 million.
Krilogy Financial LLC Purchases Shares of 1,881 HCA Healthcare, Inc. $HCA
Krilogy Financial LLC initiated a new position in HCA Healthcare (NYSE:HCA) during the third quarter, acquiring 1,881 shares valued at approximately $890,000. This move is part of a broader trend of institutional investors modifying their stakes in HCA, which has seen positive sentiment from analysts and a recent dividend increase. However, significant insider selling has also been noted, along with mixed analyst forecasts for Q1 EPS.
Understanding Momentum Shifts in (HCA)
This article provides an in-depth analysis of momentum shifts for Hca Healthcare Inc. (HCA), highlighting strong sentiment across all horizons and elevated downside risk. It outlines three distinct AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis for various holding periods. The report also encourages users to access real-time signals and personalized analysis through their platform.
ENSG Stock Price, Forecast & Analysis | ENSIGN GROUP INC/THE (NASDAQ:ENSG)
This article provides a comprehensive analysis of ENSIGN GROUP INC/THE (NASDAQ:ENSG), covering its stock price, technical and fundamental ratings, financial highlights, and analyst forecasts. ENSG currently trades at $213.34, with strong technical performance and a positive outlook for EPS and revenue growth in the coming year. The company specializes in skilled nursing, senior living, and rehabilitative care services across 17 states.
Varma Mutual Pension Insurance Co Purchases 2,400 Shares of HCA Healthcare, Inc. $HCA
Varma Mutual Pension Insurance Co increased its stake in HCA Healthcare, Inc. by 8.6% in the third quarter, purchasing an additional 2,400 shares. Several other institutional investors also adjusted their positions in HCA Healthcare. The article also details recent insider stock sales, company financial performance, and analyst ratings, noting a recent dividend increase.
Public Sector Pension Investment Board Acquires 207,070 Shares of HCA Healthcare, Inc. $HCA
The Public Sector Pension Investment Board significantly increased its stake in HCA Healthcare, acquiring an additional 207,070 shares, bringing its total holdings to 369,704 shares valued at $157.57 million. Other institutional investors similarly adjusted their positions in HCA, which currently holds a "Moderate Buy" consensus rating from analysts with an average target price of $523.27. HCA Healthcare also announced an increased quarterly dividend of $0.78 per share, while company insiders made several share sales.
HCA Healthcare, Inc. $HCA Shares Acquired by Cibc World Market Inc.
Cibc World Market Inc. increased its stake in HCA Healthcare, Inc. by 21.2% in the third quarter, now owning 36,174 shares valued at over $15 million. Other institutional investors like Caprock Group LLC and ING Groep NV also acquired new positions in the company. Insiders sold a significant number of shares, valued at nearly $7 million, in the last three months, though institutional investors still own a majority of the stock.
Insider Selling: HCA Healthcare (NYSE:HCA) SVP Sells 8,020 Shares of Stock
HCA Healthcare SVP Jennifer Berres recently sold 8,020 shares of company stock for over $4.1 million, reducing her stake by 40.07%. This transaction occurred after HCA reported strong quarterly earnings, beating expectations, and raised its quarterly dividend. The stock saw an increase of 0.7%, trading at $535.24, and maintains a "Moderate Buy" consensus rating from analysts despite some recent target price adjustments.
HCA Healthcare (NYSE:HCA) SVP Christopher Wyatt Sells 4,000 Shares of Stock
HCA Healthcare SVP Christopher Wyatt recently sold 4,000 shares of company stock for over $2 million, reducing his stake by 8.27%. This transaction occurred as HCA Healthcare reported strong quarterly earnings, beating EPS estimates, and provided positive FY2026 guidance. The company also increased its quarterly dividend, and analysts maintain a "Moderate Buy" rating with an average target price above the current trading value.
John Chidsey to lead Norwegian Cruise Line Holdings (NYSE: NCLH) as CEO
Norwegian Cruise Line Holdings Ltd. has appointed John W. Chidsey as its new President and Chief Executive Officer, effective immediately, replacing Harry Sommer. Chidsey, previously CEO of Subway Restaurants and Burger King, brings extensive experience in leading large consumer brands and will also remain on the company's Board of Directors. The company reaffirmed its fourth-quarter and full-year 2025 financial guidance, expecting Net Yields to be around the midpoint of previously disclosed ranges.
HCA Healthcare, Inc. $HCA Shares Sold by LSV Asset Management
LSV Asset Management decreased its stake in HCA Healthcare by 2.9% in Q3, selling 25,226 shares but still holding a significant position valued at $359.6 million. Concurrently, HCA's EVP Michael S. Cuffe sold 1,500 shares, reducing his ownership. The company reported strong quarterly earnings, beating expectations, and raised its quarterly dividend, while several analysts adjusted their ratings and price targets for HCA shares.
Rhumbline Advisers Sells 16,320 Shares of HCA Healthcare, Inc. $HCA
Rhumbline Advisers reduced its stake in HCA Healthcare by 5.2% in the third quarter, selling 16,320 shares and now owning 298,910 shares valued at $127.4 million. Other institutional investors also adjusted their positions, while an HCA executive sold 1,500 shares. The company recently reported strong quarterly earnings, increased its dividend, and received several analyst rating upgrades, reflecting positive market sentiment despite some neutral news items.
Zacks Research Raises Earnings Estimates for HCA Healthcare
Zacks Research has increased its FY2026 EPS estimate for HCA Healthcare to $29.31 from $28.47, while maintaining a "Hold" rating. This upgrade follows HCA's stronger-than-expected Q4 performance, with EPS of $8.01 against an expected $7.37, and the company's positive FY2026 guidance of $29.10–$31.50 EPS. Analysts generally hold a "Moderate Buy" consensus for HCA, with a price target around $523.
Caprock Group LLC Invests $5.69 Million in HCA Healthcare, Inc. $HCA
Caprock Group LLC has acquired a new stake of 14,095 shares in HCA Healthcare Inc., valued at approximately $5.69 million. Other institutional investors also adjusted their holdings in HCA, which recently reported strong earnings, beating analyst expectations, and increased its quarterly dividend to $0.78 per share. Several analysts have updated their price targets for HCA, with a consensus "Moderate Buy" rating.
Tenet Healthcare Beats Q4 Earnings: But 2026 EBITDA Margin May Decline
Tenet Healthcare (THC) reported strong fourth-quarter 2025 earnings, exceeding analyst expectations for EPS and revenue, driven by higher same-facility revenues and a favorable payer mix. Despite this, the company projects a potential decline in its adjusted EBITDA margin for 2026, even as net operating revenues are expected to increase. The article also provides financial details for THC's segments and an outlook for the coming year, alongside performance summaries of other medical companies.
Pay Less, Gain More: UHS Tops HCA Healthcare Stock
This article analyzes why Universal Health Services (UHS) stock may be a better investment than HCA Healthcare (HCA). It highlights that UHS has a lower valuation (P/OpInc) but higher revenue and operating income growth compared to HCA. The analysis also compares current metrics with those from a year prior, suggesting that HCA's underperformance in growth metrics reinforces the conclusion that its stock is expensive.
HCA Healthcare Inc (HCA) Shares Up 4.7% on Feb 11
HCA Healthcare Inc (HCA) shares rose 4.70% on February 11, reaching an intraday high of $525.64. This places the stock just below its 52-week high, with significant gains from its 52-week low. Analysts have an average target price of $528.46, indicating an "Outperform" consensus, although GuruFocus's GF Value suggests a potential downside from the current price.
